GLIPIZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Glipizide patents expire, and what generic alternatives are available?
Glipizide is a drug marketed by Aurobindo Pharma, Mylan, Par Pharm, Unique, Watson Labs, Zydus Pharms, Accord Hlthcare, Ani Pharms, Apotex, Aurobindo Pharma Usa, Barr Labs Inc, Chartwell Rx, Oxford Pharms, Rubicon, Sandoz, Sun Pharm Inds Inc, Watson Labs Teva, Dash Pharms, Epic Pharma Llc, Heritage Pharms, Teva Pharms, and Zydus Pharms Usa Inc. and is included in twenty-six NDAs.
The generic ingredient in GLIPIZIDE is glipizide; metformin hydrochloride. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the glipizide; metformin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Glipizide
A generic version of GLIPIZIDE was approved as glipizide; metformin hydrochloride by EPIC PHARMA LLC on October 27th, 2005.
Summary for GLIPIZIDE
US Patents: | 0 |
Applicants: | 22 |
NDAs: | 26 |
Finished Product Suppliers / Packagers: | 41 |
Raw Ingredient (Bulk) Api Vendors: | 123 |
Clinical Trials: | 41 |
Patent Applications: | 4,254 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for GLIPIZIDE |
Drug Sales Revenues: | Drug sales revenues for GLIPIZIDE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GLIPIZIDE |
What excipients (inactive ingredients) are in GLIPIZIDE? | GLIPIZIDE excipients list |
DailyMed Link: | GLIPIZIDE at DailyMed |
Recent Clinical Trials for GLIPIZIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Michigan | Phase 1 |
Food and Drug Administration (FDA) | Phase 1 |
Stanford University | Phase 4 |
Pharmacology for GLIPIZIDE
Drug Class | Sulfonylurea |
Medical Subject Heading (MeSH) Categories for GLIPIZIDE
Anatomical Therapeutic Chemical (ATC) Classes for GLIPIZIDE
US Patents and Regulatory Information for GLIPIZIDE
GLIPIZIDE is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting GLIPIZIDE
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Try a Trial